Blog

Ellenbarrie Industrial Gases has been awarded a contract worth ₹480.73 crore, excluding GST, by Bharat Heavy Electricals Limited (BHEL) for the supply and erection of a Cryogenic Air Separation Unit (ASU), the company disclosed in a regulatory filing dated 28 September 2026. The order alone is larger than the company’s entire FY25 standalone revenue of ₹341.6 crore.

The turnkey contract covers a proposed Coal to Ammonium Nitrate project at Bandhabal in Jharsuguda district, Odisha, with commissioning targeted for FY29. Ellenbarrie Industrial Gases shares are among those in focus following the disclosure.

What the Contract Covers

The order is for a 1,200 tonnes-per-day (TPD) Cryogenic Air Separation Unit, to be built as part of BHEL’s proposed 2,000 TPD Coal to Ammonium Nitrate project. As a turnkey contract, it covers the full project lifecycle, design, engineering, supply, erection, testing, and operator training, through to final performance guarantees, rather than a single component of the work.

Parameter	Details
Client	Bharat Heavy Electricals Limited (BHEL)
Contract Value	₹480.73 crore, excluding GST
Equipment	1,200 TPD Cryogenic Air Separation Unit (ASU)
End Project	2,000 TPD Coal to Ammonium Nitrate Project
Location	Bandhabal, Jharsuguda district, Odisha
Contract Type	Turnkey (design, supply, erection, testing)
Execution Timeline	24 months
Targeted Commissioning	FY29
Company’s FY25 Standalone Revenue	₹341.6 crore

A Cryogenic Air Separation Unit works by cooling air to extremely low temperatures to separate it into its component gases, primarily oxygen, nitrogen and argon, which are then used as industrial inputs. In this case, the unit’s output is intended to support BHEL’s ammonium nitrate production process at the Odisha site, feeding a downstream chemical process that converts coal-derived inputs into ammonium nitrate, commonly used as an industrial explosive precursor and in fertiliser production.

Why the Order’s Size Matters

The ₹480.73 crore contract value exceeds Ellenbarrie’s entire standalone revenue for FY25, making this a significant single order relative to the company’s existing scale of operations. For a company of this size, an order of this magnitude materially changes near-term order-book visibility, even though revenue recognition will be spread across the roughly two-year execution window rather than booked immediately, meaning the impact on any single quarter’s reported numbers will be gradual rather than sudden.

• The order value exceeds the company’s full FY25 standalone revenue.
• Execution is spread over 24 months, with commissioning targeted for FY29.
• The contract is turnkey, covering the full project lifecycle rather than a single scope item.
• BHEL, a Maharatna central public sector enterprise, is among India’s largest engineering and equipment manufacturers.

What Ellenbarrie Industrial Gases Does

Ellenbarrie Industrial Gases has been operating for more than 50 years, manufacturing and supplying industrial gases including oxygen, nitrogen, argon, helium, hydrogen, acetylene, carbon dioxide and nitrous oxide, alongside specialty gases. The company also supplies medical gases, dry ice, LPG, welding gas mixtures and synthetic air to a range of industrial and healthcare customers.

Winning a large turnkey ASU contract from a PSU major such as BHEL adds to the company’s technical credentials in cryogenic gas separation technology, a more complex and higher-barrier segment than standard industrial gas supply, and expands its geographic presence into the eastern industrial corridor through the Odisha project site. Coal-to-chemical projects of this kind typically require large, dedicated gas supply infrastructure, since ammonium nitrate production depends on a steady, high-volume supply of separated industrial gases as a core feedstock input.

What This Means for the Company’s Order Book

Beyond the immediate revenue visibility this single order provides, the contract reinforces Ellenbarrie’s positioning in large-scale, PSU-linked industrial gas infrastructure projects, a category that typically involves longer execution timelines but also longer-term client relationships once a plant is commissioned and operational, since gas supply agreements often extend well beyond the initial construction phase.

• The contract adds substantial medium-term revenue visibility through FY29.
• Success on this project could support future large-ticket order wins from PSU clients.
• The Odisha location expands the company’s operational footprint into eastern India.
• Long-term gas supply arrangements often follow the initial construction and commissioning phase of such projects.

What Investors Should Track Next

• Execution milestones over the 24-month construction timeline
• Any further large-ticket orders from BHEL or other public-sector clients
• Commentary on this order’s contribution to revenue and margins in upcoming quarterly results
• The commissioning timeline update as the project approaches its targeted FY29 completion

Shareholders tracking Ellenbarrie Industrial Gases can watch closely for quarterly updates on execution progress as the project advances steadily toward its FY29 commissioning target. Investors who open demat account online for industrial and infrastructure-linked stocks, and who monitor such names through a trading platform, may also want to track how this single large order compares with the company’s typical run-rate of business as more details emerge in subsequent disclosures.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.

Prasol Chemicals reported a 150.7 per cent year-on-year jump in standalone net profit to ₹61.02 crore for the quarter ended June 2026, against ₹24.34 crore in the same quarter last year, the company said in its board-approved results announced Monday, 28 September 2026. Revenue rose 35.7 per cent to ₹433.65 crore from ₹319.56 crore.

This marks Prasol Chemicals’ first quarterly result announcement since its stock market debut on 16 September 2026, making it an early test of the company’s execution track record. The specialty chemicals maker’s shares are in focus following the results.

How the Quarter Performed

Operating EBITDA more than doubled, rising about 122 per cent year-on-year to ₹90.3 crore from ₹40.7 crore, while the EBITDA margin expanded sharply to 20.8 per cent from 12.7 per cent in the same quarter last year, an increase of about 811 basis points. Gross margin also improved, to 37.9 per cent from 30.0 per cent.

Parameter	Details
Standalone Net Profit	₹61.02 crore, up 150.7% YoY from ₹24.34 crore
Revenue From Operations	₹433.65 crore, up 35.7% YoY from ₹319.56 crore
Operating EBITDA	₹90.3 crore, up about 122% YoY from ₹40.7 crore
EBITDA Margin	20.8%, up from 12.7% a year earlier
Gross Margin	37.9%, up from 30.0% a year earlier
Listing Date	16 September 2026
Quarter Reported	Q1 FY27 (quarter ended 30 June 2026)

What Drove the Improvement

Management linked the quarter’s performance to a turnaround at the company’s Mahad manufacturing facility, which recorded its best-ever quarterly production and improved capacity utilisation. The company also pointed to a richer product mix, with a shift toward higher-value secondary and tertiary derivatives in its acetone and phosphorous value chains, as a key contributor to the margin expansion.

The company disclosed that part of the quarter’s gross profit benefited from a sharp rise in average selling prices linked to geopolitical-driven supply chain disruptions, adding an estimated ₹25 crore to gross profit, along with a smaller ₹0.92 crore positive impact from foreign currency movements. These are flagged as partly non-recurring factors rather than a pure reflection of underlying operational improvement alone.

• Standalone net profit more than doubled year-on-year to ₹61.02 crore.
• The Mahad facility’s best-ever quarterly production supported the margin gains.
• A shift toward higher-value derivatives in the acetone and phosphorous chains aided profitability.
• Part of the gross profit gain is linked to a temporary pricing tailwind from supply chain disruptions.

What This Means as a First Post-Listing Result

For a company that listed only around two weeks before this results announcement, a strong first quarterly report as a public entity sets an important early reference point for how the market assesses its execution against the growth story presented ahead of its IPO. Investors will likely weigh how much of the quarter’s outperformance reflects sustainable operational gains versus temporary pricing tailwinds tied to supply chain conditions, since the two drivers carry very different implications for how future quarters might look.

The company’s IPO proceeds were primarily intended to prepay or repay higher-cost borrowings, a capital-structure move that, if executed as planned, could support margins further in coming quarters by reducing interest costs, separate from the operational improvements seen in this quarter’s results and from any pricing-related tailwinds that may not repeat.

Management’s Outlook Commentary

According to reports citing company commentary, management has set a revenue target range of ₹1,550 crore to ₹1,650 crore for the full FY27 year, and has also outlined a phased capital expenditure plan of ₹500 crore to ₹600 crore for capacity expansion. These figures represent the company’s own stated plans and targets rather than a guarantee of future performance.

• The IPO’s stated use of proceeds includes prepaying or repaying high-cost debt.
• Management has outlined a full-year FY27 revenue target range, according to reported commentary.
• A phased capex plan of ₹500-600 crore has also been outlined for future capacity expansion.
• Subsequent quarters will show whether the Q1 margin expansion proves durable or partly reverses.

What Investors Should Watch Next

• Whether the Mahad facility’s high utilisation and production levels are sustained in coming quarters
• The extent to which the pricing tailwind linked to supply chain disruptions persists or fades
• Progress on debt reduction using IPO proceeds and its effect on future interest costs
• Execution against the company’s stated FY27 revenue target and capex plans

Shareholders holding Prasol Chemicals stock can track how the company’s subsequent quarterly results compare with this strong opening result as a newly listed entity. Investors who open demat account online to participate in newly listed specialty chemicals names, and who monitor such stocks on a trading platform, may also want to separate the one-time pricing benefit flagged by management from the underlying operational gains at the Mahad facility when assessing the sustainability of this quarter’s reported margins.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.

NCC Ltd has received a Letter of Acceptance worth ₹1,076.71 crore, excluding GST, from the Rural Water Supply and Sanitation Department, Visakhapatnam, Government of Andhra Pradesh, the Hyderabad-based construction and infrastructure company said in a regulatory filing on Monday, 28 September 2026. The order covers a drinking water supply project under the Multi Village Scheme linked to the Yeleru Reservoir.

The company said it accepted the Letter of Acceptance, dated 26 September 2026, on 28 September. NCC shares are among those in focus on Tuesday following the disclosure, alongside other infrastructure and construction names reporting fresh order wins this week.

What the Order Covers

The project involves providing drinking water supply infrastructure under the Multi Village Scheme on the Yeleru Reservoir for the Anakapalli segment in Anakapalli district, Andhra Pradesh. The scheme is designed to draw water from the reservoir and distribute it to multiple villages within the segment through a shared supply network, a common approach for rural water infrastructure projects that serve several settlements from a single source rather than building separate systems for each village.

The contract is scheduled for completion within 24 months from the start of execution, giving NCC a defined medium-term revenue visibility window tied to this single order.

Parameter	Details
Client	Rural Water Supply and Sanitation Department, Visakhapatnam, Government of Andhra Pradesh
Order Value	₹1,076.71 crore, excluding GST
Project Type	Drinking water supply, Multi Village Scheme
Water Source	Yeleru Reservoir
Location	Anakapalli segment, Anakapalli district, Andhra Pradesh
Letter of Acceptance Date	26 September 2026
Execution Timeline	24 months

Why This Order Matters for NCC

Water and irrigation projects have been a recurring segment for NCC alongside its broader portfolio in buildings, roads and other infrastructure categories. Government-funded rural water supply schemes of this scale add to the company’s order book in a segment where demand has remained relatively steady, driven by ongoing state-level infrastructure programmes across India.

NCC has secured multiple large orders from Andhra Pradesh-related government bodies in the recent past, including infrastructure work for the Amaravati Capital City project, where the company previously won a ₹2,129.60 crore order covering roads, drainage, water supply, sewage and utility ducts. The state has been a consistent source of large-ticket infrastructure awards for the company across several project categories.

• The order is a 100 per cent government contract with no related-party involvement.
• A 24-month execution window gives a defined near-to-medium-term timeline for revenue recognition.
• Water and irrigation projects remain one of NCC’s established business segments.
• Andhra Pradesh has been a recurring source of large infrastructure orders for the company.

What Could Affect Execution

Projects of this kind typically depend on a combination of factors outside any single company’s direct control, including timely administrative and environmental clearances, right-of-way access along the reservoir-linked pipeline route, and stable pricing for key inputs such as steel, cement and pipes over the execution period.

Payment timelines from the state government department are also a factor construction companies commonly watch on large public-sector infrastructure orders, since working-capital cycles on such projects can be affected by the pace of milestone-based billing and clearance. Delays in any of these areas can push out the completion timeline or affect the margin profile of a fixed-scope contract, which is why execution updates over the life of the project matter as much as the initial order announcement.

NCC’s Broader Order Book Context

This order adds to a series of contract wins NCC has reported through the year. Earlier in 2026, the company had also entered the smart meters segment, securing projects worth a combined ₹8,080 crore, marking a diversification beyond its traditional construction categories and adding a technology-linked revenue stream to a business historically centred on physical construction and civil works.

In July 2026, NCC received separate orders worth ₹1,052.7 crore, split between its Buildings Division (₹590.3 crore) and Water Division (₹462.3 crore), indicating that water-segment order wins of this scale have been a recurring feature of the company’s recent business activity rather than a one-off event tied to a single state or client.

What Investors Should Track Next

• Formal execution milestones and progress updates on the Anakapalli water supply project
• Payment cycle performance from the Andhra Pradesh government department
• Contribution of this order to NCC’s overall order book and revenue guidance in upcoming quarterly results
• Further order wins across NCC’s water, buildings and smart-meter segments

Shareholders tracking NCC can watch for updates on execution progress and payment milestones as the 24-month project timeline advances. Investors who open free demat account online for infrastructure and construction sector stocks, and who follow such names on a trading platform, may also want to track how this order compares with NCC’s other recent water-segment wins when assessing the company’s overall order-book momentum.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.

Peak XV Partners, Sequoia Capital and Redwood Trust are likely to sell a combined 2.73 per cent stake in Honasa Consumer, the parent of the Mamaearth and The Derma Co brands, for up to ₹400 crore, according to a CNBC-TV18 report citing sources on Monday, 28 September 2026. The shares are expected to be sold at a floor price of ₹450 apiece through a block deal.

Honasa Consumer shares closed at ₹465.05 on the BSE on Monday, meaning the reported floor price sits below the prior closing level. The stock is among those in focus on Tuesday ahead of the anticipated transaction.

What the Stake Sale Involves

The three investors are reportedly set to offload up to about 89 lakh shares in total through block deals, representing roughly 3.44 per cent of the company’s equity at the reported figures, slightly above the 2.73 per cent headline stake cited in early reports. A 45-day lock-up on further share sales by the same investors is expected to apply once the transaction completes.

Parameter	Details
Sellers	Peak XV Partners, Sequoia Capital, Redwood Trust
Stake Being Sold	About 2.73% (reports vary up to 3.44%)
Shares Involved	Up to about 89 lakh shares
Floor Price	₹450 per share
Deal Size	Up to ₹400 crore
Prior BSE Close	₹465.05
Lock-Up After Sale	45 days on further sales

Peak XV Partners, Sequoia and Redwood Trust are among Honasa’s early institutional backers, having invested well before the company’s public listing. Their gradual reduction in holding is part of a pattern of periodic partial exits that has played out since Honasa’s stock market debut.

A History of Periodic Investor Exits

This is not the first time these investors have trimmed their Honasa holdings. In September 2024, Peak XV Partners and four other early investors, including Sofina Ventures, Stellaris Venture Partners and Sequoia Capital Global Growth Fund, together sold a 10 per cent stake in the company for about ₹1,601 crore, while ICICI Prudential Life Insurance and Morgan Stanley picked up stakes in that transaction.

Honasa listed in October 2023 through a ₹1,701 crore IPO priced at ₹324 per share. The stock’s price movement since listing means early investors have periodically found opportunities to book partial gains while retaining a meaningful residual holding in the company.

• Peak XV, Sequoia and Redwood Trust are reported sellers in this latest transaction.
• The floor price of ₹450 is below Monday’s closing price of ₹465.05.
• A similar, larger stake sale by overlapping investors took place in September 2024.
• The 45-day lock-up is intended to limit further supply pressure immediately after the deal.

Why This Matters for the Stock

A block deal of this size can create a near-term supply overhang on the stock, since a large volume of shares changes hands outside the normal order book, often at a discount to the prevailing market price. Whether the stock holds above the ₹450 floor price once trading begins will be an early signal of demand from buyers stepping in to absorb the block.

At the same time, a partial exit by early institutional backers does not, on its own, change Honasa’s underlying business fundamentals, its brand portfolio, distribution reach or profitability trajectory. Some market participants may read repeated partial exits by the same set of early investors as a sign of a maturing shareholder base, while others may see it as reduced conviction at current valuations.

Honasa has been working to expand beyond its flagship Mamaearth brand, scaling its derma-focused portfolio, including The Derma Co and Aqualogica, and building out its offline retail distribution alongside its established online and quick-commerce presence. The company has previously stated an intention to widen its offline footprint significantly over the coming years, a strategy that sits separately from the ownership changes at the shareholder level reflected in Monday’s reported stake sale.

What Investors Should Watch Next

• Whether the block deal executes at or above the ₹450 floor price
• Formal exchange disclosures confirming the sellers, buyers and final transaction size
• The stock’s trading pattern in the sessions immediately following the deal
• Any commentary from brokerages on how the transaction affects near-term sentiment

Shareholders can watch for the formal bulk or block deal disclosure on the exchanges, typically published within a day of such a transaction. Investors who open demat account online to track consumer and beauty-sector stocks may also want to watch the stock’s price action on a trading platform in the sessions right after the deal, since that reaction often shows how the market is reading the supply overhang.

This kind of periodic investor stake sale is common in recently listed, venture-backed consumer companies, and does not necessarily signal a change in the company’s own operating performance.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.

Reliance Jio added the highest number of wireless mobile subscribers among Indian telecom operators in August 2026, gaining nearly 2.40 million users, followed by Bharti Airtel with about 2.11 million additions, according to data released by the Telecom Regulatory Authority of India (TRAI) on Monday, 28 September 2026. India’s total wireless subscriber base crossed 1.31 billion during the month, continuing a long streak of steady month-on-month growth in the country’s telecom market.

The data, released as part of TRAI’s routine monthly disclosure, also showed Vodafone Idea and state-run BSNL posting smaller gains, while MTNL recorded subscriber losses. Telecom stocks are among those in focus on Tuesday following the release, which TRAI compiles monthly from operator-reported connection data across telecom circles spanning the country.

How the Wireless Market Grew in August

India’s total wireless subscribers, including mobile and Fixed Wireless Access (FWA) connections, rose from 1,306.27 million at the end of July to 1,312.25 million at the end of August, a monthly growth rate of 0.46 per cent. Wireless mobile subscribers alone rose from 1,287.92 million to 1,293.43 million, up 0.43 per cent.

Parameter	Details
Reliance Jio Subscriber Additions	About 2.40 million, taking its base to 508.43 million (39.31% market share)
Bharti Airtel Subscriber Additions	About 2.11 million, taking its base to 491.60 million (38.01% market share)
Vodafone Idea Subscriber Base	About 199.57 million
BSNL Subscriber Base	About 93.67 million
Total Wireless Subscribers (India)	1,312.25 million, up 0.46% month-on-month
Wireless Tele-Density	Rose to 91.69% from 91.33%
Private Operators’ Market Share	92.75% of wireless mobile subscribers

Urban wireless subscriptions grew from 753.86 million to 759.11 million during August, a 0.70 per cent increase, while rural subscriptions rose from 552.40 million to 553.14 million, up 0.13 per cent. The faster urban growth rate suggests city markets remained the primary driver of net additions during the month, even though rural India still accounts for a substantial share of the overall subscriber base.

Broadband and 5G Fixed Wireless Trends

Jio also retained its lead in India’s broadband market, with 538.03 million broadband subscribers at the end of August, ahead of Airtel’s 386.39 million, Vodafone Idea’s 130.88 million and BSNL’s 27.82 million. The top five broadband providers together accounted for 98.58 per cent of the market, underscoring how concentrated India’s fixed and wireless broadband segment has become among a small number of large operators.

In the 5G Fixed Wireless Access segment, total subscribers rose to 13.45 million in August, an increase of about 245,000 from July. Jio accounted for roughly 9.42 million of those connections, adding 148,870 during the month, while Airtel held about 4.03 million. Fixed Wireless Access uses 5G network infrastructure to deliver home or office broadband without a physical fibre or copper line into the premises, making it a lower-cost way for operators to extend broadband reach into areas where laying fixed-line infrastructure is less economical.

• Jio led both mobile subscriber additions and 5G FWA growth in August.
• Airtel remained a close second in mobile additions, with a narrower market-share gap than in some previous months.
• Machine-to-machine (M2M) cellular connections rose from 137.70 million to 140.50 million.
• India’s overall telephone subscriber base, including wireline, reached 1,360.70 million, up 0.47%.

M2M connections link devices such as smart meters, vehicle trackers and industrial sensors to cellular networks rather than to individual human subscribers, and this category has been growing steadily as utilities and logistics firms expand connected-device deployments across the country.

What This Means for Telecom Investors

The TRAI data offers a monthly snapshot of how India’s telecom operators are performing on subscriber growth, a key metric investors track alongside average revenue per user (ARPU) and capital expenditure when assessing the sector. Jio’s continued lead in both mobile and broadband additions, alongside its 5G FWA growth, reinforces its position as the subscriber-growth leader, though Airtel’s additions remain close enough to keep the competitive gap narrow.

• Jio and Airtel together continue to account for the large majority of net new subscribers each month.
• Vodafone Idea’s slower growth relative to Jio and Airtel remains a recurring theme in monthly TRAI data.
• 5G FWA adoption is still a relatively small but fast-growing segment within the broader wireless base.
• M2M connections, tied to industrial and utility use cases, continue to expand steadily.

Investors who open demat account online to track telecom-sector holdings can use this monthly TRAI release as one data point among several, alongside quarterly ARPU and capex disclosures, when assessing operator performance. Those following the sector on a trading platform may also want to watch how 5G FWA additions trend in the coming months, since this segment remains an emerging growth area rather than a mature one, and TRAI’s monthly subscriber releases, published in the days following each month’s end, offer a recurring reference point.

Disclaimer: This article reports on regulatory data and does not constitute investment advice.

Clean Max Enviro Energy Solutions shares rose more than 5 per cent in intraday trade on Monday, 28 September 2026, defying broader market weakness, after a block deal saw 8.6 million shares of the company change hands. The move came even as the benchmark Nifty 50 was down more than 1 per cent during the session.

As of 10 am, Clean Max Enviro Energy Solutions shares were trading 3.2 per cent higher at ₹1,439 on the NSE, making it the most active stock on the exchange by traded value.

What Happened in the Block Deal

According to Bloomberg data, a total of 8.6 million shares of Clean Max Enviro Energy Solutions changed hands in a single block on Monday. Further details of the parties involved were not immediately available at the time of the trade.

Media reports indicated that Augment India Holdings may have sold more than 7 per cent of its total stake in the company for approximately ₹1,062 crore, at a floor price of around ₹1,250 per share. According to NSE data, around 12 million shares of the company changed hands overall during the session, amounting to ₹1,573.34 crore in traded value.

Parameter	Details
Shares Traded in Block	8.6 million shares
Reported Seller	Augment India Holdings (media reports)
Reported Stake Sold	More than 7% of total holding
Reported Deal Value	About ₹1,062 crore
Reported Floor Price	About ₹1,250 per share
Total NSE Volume (Session)	About 12 million shares, ₹1,573.34 crore
Stock Price (10 am)	₹1,439, up 3.2%
Comparison to Nifty 50	Nifty down over 1% at the same time

How the Stock Performed Against the Broader Market

The Nifty 50 was down 265 points, or 1.15 per cent, at 23,870 around the time Clean Max Enviro’s stock was trading higher, underscoring how sharply the counter diverged from the broader market trend on the day. The stock’s status as the most active counter on the NSE by value reflected the scale of trading activity concentrated in the name during the session.

Harish Jujarey, AVP equity research at Prithvi Finmart, said the stock remains within a broader consolidation range despite Monday’s intraday move of 5-6 per cent, and noted that its daily chart is forming a pattern that some technical analysts read as suggesting further upside is possible if a breakout occurs. Such chart-based observations reflect one analyst’s reading of price action and are not a guarantee of how the stock will move.

• Clean Max Enviro rose over 5% intraday while the Nifty 50 fell more than 1%.
• The block deal involved 8.6 million shares, with total session volume around 12 million shares.
• Media reports point to Augment India Holdings as the likely seller of the block.
• The company’s identity as India’s largest renewable energy solutions provider for commercial and industrial clients adds context to investor interest in the stock.

About Clean Max Enviro Energy Solutions

Clean Max Enviro Energy Solutions describes itself as the largest renewable energy solutions provider for the commercial and industrial sector in India. The company made its stock market debut on Dalal Street in March 2026.

At current levels, the stock trades well above its IPO price of ₹1,053, roughly 37 per cent higher. The company’s most recent quarterly results showed a sharp improvement in profitability: revenue for the quarter ended June 2026 (Q1 FY27) rose more than 100 per cent year-on-year to ₹832 crore, EBITDA increased 74 per cent to ₹494 crore, and the company swung to a net profit of ₹55 crore from a net loss of ₹17 crore in the same quarter a year earlier.

What Investors Should Watch Next

The identity of the buyer in Monday’s block deal has not been officially confirmed, and neither has a formal exchange filing detailing the transaction at the time of reporting. Investors will likely look for such a filing to confirm the seller’s identity and the exact terms of the trade.

• Confirmation of the buyer and seller through a formal exchange disclosure
• Whether the reported stake sale by Augment India Holdings, if confirmed, signals a broader change in shareholding pattern
• The stock’s behaviour in subsequent sessions once the immediate block-deal reaction settles
• Continued tracking of the company’s quarterly results given its recent swing to profitability

Shareholders tracking Clean Max Enviro through a demat and trading account can watch for the formal bulk or block deal disclosure on the exchanges, which typically follows within a day or two of such a large trade. Investors reviewing the stock through an online trading platform may also want to note that its performance diverged sharply from the broader market on Monday, which is worth separating from the fundamentals reflected in its recent quarterly numbers.

Disclaimer: This article reports on a market event based on exchange and media data. It is for informational purposes only and does not constitute investment advice.

Shares of Jyoti CNC Automation fell as much as 3.7 per cent to ₹1,025 on the National Stock Exchange (NSE) in intraday trade on Monday, 28 September 2026, after a fire broke out at the company’s manufacturing facility in Metoda, Rajkot, over the weekend. The company said the blaze was brought under control within 30 to 60 minutes and that operations have since resumed.

Monday was the first trading session after the fire, which occurred on Saturday, 26 September. No casualties or injuries were reported in the incident.

What Happened at the Rajkot Facility

The fire broke out in the assembling unit at Jyoti CNC’s factory in Metoda GIDC, a major industrial area in Rajkot district, during the morning hours on Saturday. Thick black smoke was visible from the premises, causing alarm among employees and nearby units, and the local fire brigade was alerted and responded to the site.

Jyoti CNC said in its statement that the situation was brought under control within 30 to 60 minutes of the fire breaking out, and that no casualties or injuries occurred. The company added that operations at the facility have since resumed.

Local Gujarati media reported that the fire triggered visible panic among employees and workers at nearby units in the Metoda GIDC industrial estate as thick black smoke rose from the premises, drawing local fire brigade teams to the site before the blaze was brought under control.

Parameter	Details
Date of Fire	Saturday, 26 September 2026
Location	Metoda GIDC, Rajkot, Gujarat
Unit Affected	Assembling unit
Time to Contain	30 to 60 minutes
Casualties or Injuries	None reported
Operational Status	Resumed
Stock Reaction (Monday, NSE)	Fell as much as 3.7% to ₹1,025

How the Stock Reacted on Monday

Monday, 28 September, was the first trading session since the fire, and investors turned bearish on the stock in early deals. Jyoti CNC shares fell as much as 3.7 per cent to touch ₹1,025 on the NSE in intraday trade, before the broader tone of the session continued to weigh on sentiment.

The reaction reflects investor caution around potential disruption to the company’s manufacturing operations, even though Jyoti CNC has stated that the fire was contained quickly and that operations have resumed. The stock’s fall came against a backdrop of broader market weakness on Monday, with the Sensex and Nifty both trading lower during the session.

• The fire broke out on Saturday, 26 September, in the assembling unit at Rajkot.
• Jyoti CNC says the fire was contained within 30 to 60 minutes with no casualties.
• Operations at the facility have resumed, according to the company.
• The stock fell as much as 3.7% in Monday’s session, its first trading day after the incident.

What Jyoti CNC Does

Jyoti CNC Automation is a manufacturer of simultaneous 5-axis CNC machines and a range of computer numerical control machine tools, serving sectors including aerospace, defence, automotive and general engineering. The company’s manufacturing base is centred in Rajkot, Gujarat, where it has operated since its founding.

The Metoda GIDC facility affected by the fire is part of the company’s broader manufacturing footprint in the region, which includes multiple production units supporting its CNC machine and component output. Jyoti CNC holds roughly a 10 per cent share of India’s CNC machine manufacturing market and employs about 2,700 people.

For the quarter ended 30 June 2026 (Q1 FY27), the company reported consolidated revenue of ₹508.5 crore and consolidated profit after tax of ₹57.1 crore, with its French subsidiary facing interim restrictions during the period. The fire comes just ahead of Jyoti CNC’s annual general meeting, scheduled for Wednesday, 30 September 2026, at the company’s Lodhika GIDC premises in Rajkot district, where shareholders may seek an update on the incident.

What Investors Should Watch Next

Jyoti CNC has not disclosed a specific financial or production impact from the fire beyond confirming that operations have resumed. Investors and analysts will likely look for further detail in the company’s upcoming disclosures on whether the incident caused any measurable disruption to output or delivery timelines.

• Any formal exchange filing detailing the cause and extent of the fire damage
• Whether the incident affects near-term production or delivery schedules
• Commentary on the incident, if any, in the company’s next quarterly results
• How the stock recovers in subsequent sessions once the immediate reaction settles

Shareholders holding Jyoti CNC in a demat and trading account can watch for a formal exchange filing on the incident, since the company’s public statement so far has been limited to confirming containment and resumption of operations. Investors tracking the stock through an online trading platform may also want to separate Monday’s fire-related reaction from the broader market weakness that affected most stocks during the session.

Disclaimer: This article is based on company statements and media reports on the incident. It is for informational purposes only and does not constitute investment advice.

Shares of the National Stock Exchange of India (NSE) fell below their ₹1,785 issue price for the first time since listing, hitting an intraday low of ₹1,761 on the BSE on Monday, 28 September 2026. The stock is now trading more than 6 per cent below the ₹1,878 peak it touched on its listing day.

The decline came amid broader weakness across the market, with NSE among several stocks trading lower in Monday’s session. NSE shares remain in focus as investors assess the stock’s post-listing trajectory just four trading sessions after its debut.

How Far NSE Has Fallen From Its Peak

NSE listed on the BSE on 24 September 2026 at ₹1,800 per share, a premium of 0.84 per cent over its ₹1,785 issue price. The stock climbed to an intraday high of ₹1,878 on listing day before closing at ₹1,818.

By Monday, the stock had given up all of that listing-day gain and more. At around 9:26 am, NSE was quoted 1.7 per cent lower at ₹1,762, compared with a 1 per cent decline in the BSE Sensex at the same time. About 1.1 million equity shares changed hands on the BSE during the session.

Parameter	Details
IPO Issue Price	₹1,785 per equity share
Listing Price (24 Sept)	₹1,800 per equity share
Listing-Day High	₹1,878 per equity share
Monday’s Intraday Low	₹1,761 per equity share
Fall From Listing-Day High	About 6.2%
Fall Below Issue Price	About 1.3% at the day’s low
Shares Traded (BSE, by 9:26 am)	About 1.1 million equity shares

This marks the first session in which NSE has traded below its issue price since its market debut four sessions earlier. In the previous session, the stock had already shown signs of cooling, trading about 0.56 per cent lower and dipping to an intraday low of ₹1,790 on the BSE, marginally above the listing price at the time.

Since its debut, NSE’s market capitalisation has contracted by more than ₹12,000 crore. The company finished its first trading day valued at roughly ₹4.5 lakh crore, a figure that had eased to about ₹4.37 lakh crore during Monday’s session as the stock extended its slide.

What’s Driving the Broader Weakness

NSE’s decline has come alongside a wider market sell-off rather than any company-specific announcement. The BSE Sensex itself was down about 1 per cent at the same point in Monday’s session, meaning NSE’s fall was roughly in line with, though somewhat sharper than, the overall market move.

• NSE listed at a 0.84% premium to its issue price on 24 September.
• The stock’s listing-day high of ₹1,878 has not been retested since.
• Monday’s low of ₹1,761 is below the ₹1,785 issue price for the first time.
• The move coincides with a broader decline in the Sensex and Nifty this week.

What Brokerages Have Said About NSE’s Valuation

Angel One, in commentary cited alongside the stock’s Monday move, pointed to NSE’s dominant market position, higher revenue and profitability, and strong market share in equity derivatives as factors providing comfort on the exchange operator’s business quality, even as the stock corrects from its listing-day highs.

The brokerage also flagged that NSE derives a significant portion of its revenue, 78.65 per cent in FY26, from transaction charges, with options and futures trading among the key contributors. That concentration makes the company’s financial performance sensitive to any decline in trading volumes caused by regulatory tightening on derivatives, a higher securities transaction tax (STT), a broader economic slowdown, or disruptions to its own operational and IT infrastructure.

What This Means for NSE Shareholders

For investors who received allotment in the NSE IPO, the stock trading below its issue price for the first time is a milestone worth noting, even if it reflects broader market conditions as much as anything specific to NSE. Retail investors who applied at the ₹1,785 issue price are now sitting on a paper loss at the day’s lows, having briefly been in the money after the listing-day pop.

• The current move reflects a broader market correction, not a company-specific disclosure.
• NSE’s revenue remains concentrated in transaction charges from derivatives trading.
• Regulatory changes affecting options and futures volumes are a key variable to watch.
• The stock’s behaviour around the ₹1,785 issue price level may be watched closely in coming sessions.

Shareholders tracking NSE through a demat and trading account can watch how the stock behaves around the ₹1,785 issue-price level in the coming sessions, since a sustained move below that level would mark a shift from the stock’s early post-listing pattern. Investors reviewing the position through a trading platform may also want to track NSE’s own disclosures on trading volumes and derivative segment activity, given how directly the brokerage commentary ties the company’s earnings to that business line.

Disclaimer: Brokerage views cited are those of the respective firm and are not endorsed by Findoc. This article is for informational purposes only and does not constitute investment advice.

Sun Pharmaceutical Industries has signed a global licensing agreement with US-based LIB Therapeutics for lerodalcibep, a once-monthly drug used to lower “bad” cholesterol, giving it exclusive rights to commercialise and manufacture the medicine outside the US and China. The company disclosed the deal in an exchange filing on Monday, 28 September 2026.

The agreement gives Sun Pharma access to a $3.7 billion market for PCSK9 inhibitors, a class of cholesterol-lowering medicines, outside the US and China. Sun Pharma shares are in focus following the announcement.

What the Licensing Deal Covers

Under the agreement, Sun Pharma gets exclusive rights to commercialise and manufacture lerodalcibep worldwide, excluding the US and China. The company will also be responsible for pursuing regulatory approvals in licensed territories where the drug has not yet been approved.

LIB Therapeutics will receive an upfront payment, future milestone payments, and royalties based on net sales in the licensed territories. Other financial terms of the deal remain confidential.

Parameter	Details
Drug	Lerodalcibep, a once-monthly PCSK9 inhibitor
Brand Name (EU)	Lyrokaul
EU Approval Date	21 September 2026
Territory Licensed to Sun Pharma	Worldwide, excluding the US and China
Target Market Size (Ex-US, Ex-China)	$3.7 billion (12 months to Q2 2026)
Market Growth Rate	38% CAGR over the preceding two years
Europe’s Share of the Market	$2.9 billion
Dosage Form	300 mg subcutaneous injection, once monthly

What the Drug Does

Lerodalcibep is a once-monthly PCSK9 inhibitor designed to lower low-density lipoprotein cholesterol (LDL-C), commonly referred to as “bad” cholesterol. In the European Union, it is approved under the brand name Lyrokaul for adults with hypercholesterolaemia and mixed dyslipidaemia, administered as a 300 mg subcutaneous injection once a month.

In the United States, the drug is separately approved under the brand name Lerochol as an adjunct to diet and exercise, to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. That US approval and the Chinese market are excluded from Sun Pharma’s licensing rights under this deal.

• Sun Pharma gets exclusive rights to commercialise and manufacture lerodalcibep outside the US and China.
• The drug received European Union approval on 21 September 2026, just days before this licensing deal.
• LIB Therapeutics will earn an upfront payment, milestones and net-sales royalties from the arrangement.
• The addressable market has grown at a 38% compound annual rate over the past two years.

Why This Market Matters

According to IQVIA data cited by the companies, the PCSK9 inhibitor market outside the US and China reached $3.7 billion in the 12 months ended Q2 2026, growing at a 38 per cent compound annual growth rate over the preceding two years. Europe alone accounted for $2.9 billion of that market during the period.

PCSK9 inhibitors work through a different mechanism than statins, the more commonly prescribed cholesterol-lowering drugs, and are typically used in patients who need additional LDL-C reduction beyond what statins alone can achieve. The category’s rapid growth reflects rising diagnosis and treatment of high cardiovascular risk patients globally.

What Sun Pharma’s Management Said

Kirti W Ganorkar, managing director of Sun Pharma, said the once-monthly dosing of lerodalcibep, combined with its LDL-C reduction, small injection volume and six-month ambient storage, simplifies treatment and offers greater convenience for patients.

Evan Stein, chief operating and scientific officer and co-founder of LIB Therapeutics, said Sun Pharma’s international presence and experience in building global innovative brands make it an ideal partner to bring lerodalcibep to more patients. He added that the companies aim to expand access for patients with cardiovascular disease, or at high cardiovascular risk, who need substantial additional LDL-C reductions despite existing treatment.

What This Means for Sun Pharma Shareholders

The deal adds a licensed, already EU-approved product to Sun Pharma’s innovative medicines portfolio, rather than an early-stage pipeline asset still years from market. That distinction matters for how quickly the drug could begin contributing to the company’s international business, since regulatory clearance in the European Union has already been secured.

• The deal is a licensing and manufacturing agreement, not an acquisition of LIB Therapeutics.
• Revenue contribution will depend on regulatory approvals in other licensed territories beyond the EU.
• Financial terms beyond the general royalty and milestone structure were not disclosed.
• The US and China markets remain outside Sun Pharma’s rights under this specific agreement.

Shareholders tracking Sun Pharma through a demat and trading account can watch for further disclosures on the launch timeline in Europe and other markets, since the EU approval is recent and commercial rollout details have not yet been detailed. Investors following the stock on a trading platform may also want to track how this licensing deal fits alongside Sun Pharma’s broader innovative medicines strategy in its coming quarterly disclosures.

PCSK9 inhibitors as a category have grown in relevance for patients who remain above guideline-recommended LDL-C goals despite being on statin therapy. Observational data across European countries has shown that only a minority of patients on stable oral lipid-lowering therapy achieve their risk-based cholesterol targets, underscoring the addressable need this class of drugs is designed to meet.